Benzothiazoles
AssigneeHoffmann-La Roche Inc.
InventorsAlexander Flohr, Roland Jakob-Roetne, Roger David Norcross, Claus Riemer
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of the formula 1 wherein R1 and R2 are as described within. The compounds of formula I have been found to be adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they may be used in the treatment of diseases, related to this receptor.
Claims23
A compound of the formula I
- 17
- wherein
- R1 is 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, 5,6-dihydro-4H-pyran-2-yl, tetrahydropyran-2,3 or 4-yl, cyclohex-1-enyl, cyclohexyl, substituted or unsubstitited 1,2,3,6-tetrahydro-pyridin-4-yl or substituted or unsubstituted piperidin-4-yl, wherein when R1 is substituted, the substituent is —C(O)CH3 or —C(O)OCH3 in the 1-position of the N-atom;
- R2 is lower alkyl, piperidin-1-yl, piperidin-1-yl substituted by hydroxy, phenyl, phenyl substituted by —(CH2)n—N(R′)—C(O)—(CH2)n—NR′2, —(CH2)2-halogen) lower alkyl or —(CH2)n—N(R′)—(CH2)n—O-lower alkyl, morpholinyl, pyridinyl, or pyridinyl substituted by halogen, —N(R′)—(CH2)n—O-lower alkyl, lower alkyl, lower alkoxy, morpholinyl or —(CH2)1,-pyrrolidinyl;
- n is 0, 1 or 2;
- R′ is hydrogen or lower alkyl;
- and pharmaceutically acceptable acid addition salts thereof.
A method of treating a disease mediated by the adenosine receptor comprising administering to a patient in need of such treatment, an effective amount of a compound of the formula I
- 26
- wherein
- R1 is 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, 5,6-dihydro-4H-pyran-2-yl, tetrahydropyran-2,3 or 4-yl, cyclohex-1-enyl, cyclohexyl, substituted or unsubstituted 1,2,3,6-tetrahydro-pyridin-4-yl or substituted or unsubstituted piperidin-4-yl, wherein when R1 is substituted, the substituent is —C(O)CH3 or —C(O)OCH3 in the 1-position of the N-atom;
- R2 is lower alkyl, piperidin-1-yl, piperidin-1-yl substituted by hydroxy, phenyl, phenyl substituted by —(CH2)n—N(R′)—C(O)—(CH2)n—NR′2, —(CH2)n-halogen, lower alkyl or —(CH2)n—N(R′)—(CH2)n—O-lower alkyl, morpholinyl, pyridinyl, or pyridinyl substituted by halogen, —N(R′)—(CH2)n—O-lower alkyl, lower alkyl, lower alkoxy, morpholinyl or —(CH2)n-pyrrolidinyl;
- n is 0, 1 or 2;
- R′ is hydrogen or lower alkyl;
- and pharmaceutically acceptable acid addition salts thereof.
A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula I
- 27
- wherein
- R1 is 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, 5,6-dihydro-4H-pyran-2-yl, tetrahydropyran-2,3 or 4-yl, cyclohex-1-enyl, cyclohexyl, substituted or unsubstituted 1,2,3,6-tetrahydro-pyridin-4-yl or substituted or unsubstituted piperidin-4-yl, wherein when RI is substituted, the substituent is —C(O)CH3 or —C(O)OCH3 in the 1-position of the N-atom;
- R2 is lower alkyl, piperidin-1-yl, piperidin-1-yl substituted by hydroxy, phenyl, phenyl substituted by —(CH2)n—N(R′)—C(O)—(CH2)n—NR′2, —(CH2)n-halogen, lower alkyl or —(CH2)n—N(R′)—(CH2)n—O-lower alkyl, morpholinyl, pyridinyl, or pyridinyl substituted by halogen, —N(R′)—(CH2)n—O-lower alkyl, lower alkyl, lower alkoxy, morpholinyl or —(CH2)n-pyrrolidinyl;
- n is 0, 1 or 2;
- R′ is hydrogen or lower alkyl;
- and pharmaceutically acceptable acid addition salts thereof;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.